Comparison of Nicotine Pharmacokinetics in Healthy Japanese Male Smokers Following Application of the Transdermal Nicotine Patch and Cigarette Smoking

Sobue, Satoshi; Sekiguchi, Kaneo; Kikkawa, Hironori; Akasaki, Moriaki; Irie, Shin

doi:10.1248/bpb.29.1068

Cited by 14 publications

(5 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, although this was a safety/dose escalation study, more subjects with high antibody responses quit smoking during the trial than did those with lower antibody responses, even though subjects were not asked to quit smoking. The NicQb vaccine also elicited significant quantities of anti-NIC antibodies [30], and a similar observation was made that subjects in the upper third of antibody responses had almost double the quit rate of placebo subjects (57% vs 31%). Subjects in the TA-NIC vaccine trial were immunized with four doses over the first 8 weeks and then given a booster dose at 32 weeks.…”

Section: Antibody and Drug Pharmacodynamics And Pharmacokineticssupporting

confidence: 56%

The future of vaccines in the management of addictive disorders

Orson¹,

Kinsey²,

Singh³

et al. 2007

Curr Psychiatry Rep

View full text Add to dashboard Cite

Conventional substance abuse treatments have had only limited success. As a result, new approaches, including vaccination to block the effects of drugs such as cocaine, nicotine, methamphetamine, and phencyclidine, are in development. Although a number of possible rationales for the effects of antidrug vaccines have been suggested, the most straightforward and intuitive mechanism would involve binding of the drug by antibodies in the bloodstream, thereby blocking entry or reducing the rate of entry of the drug into the central nervous system. The theoretical parameters that would influence vaccine-induced drug pharmacodynamics are presented in this review, along with the current status on vaccine development for nicotine, cocaine, methamphetamine, and phencyclidine.

show abstract

Section: Antibody and Drug Pharmacodynamics And Pharmacokineticssupporting

confidence: 56%

The future of vaccines in the management of addictive disorders

Orson¹,

Kinsey²,

Singh³

et al. 2007

Curr Psychiatry Rep

View full text Add to dashboard Cite

show abstract

“…Therefore, it is a reliable indicator of recent nicotine intake [7]. However, for patients undergoing nicotine replacement therapy (NRT) using nicotine gum and nicotine patches, cotinine cannot be used as an indicator of smoking cessation because nicotine and cotinine are present at the same levels as smokers [8][9][10][11][12]. On the other hand, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in urine has been reported as an exposure indicator that is not affected by NRT [13,14].…”

Section: Introductionmentioning

confidence: 99%

Effects of smoking cessation on biological monitoring markers in urine

Kawasaki

Ootsuyama

et al. 2020

Genes and Environ

View full text Add to dashboard Cite

Introduction Urinary nicotine and cotinine levels are often measured as biomarkers for tobacco smoke exposure. However, these biomarkers are not appropriate to evaluate the effects of quitting smoking for several days, because of their short half-lives. In this study, we focused on the changes in the urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) levels of 55 patients in a smoking cessation program, because of the long half-life. At the same time, urinary 7-methylguanine (m7Gua) and 8-hydroxy-2′-deoxyguanosine (8-OHdG), as DNA damage markers of cigarette smoking, were also measured. Results In the subjects who completed the quit-smoking program (18 subjects out of 55), the urinary nicotine and cotinine levels decreased to 1.7 and 0.2% at 8 weeks after the first visit to the clinic. By contrast, the NNAL levels decreased to 12.3% at 8 weeks after quitting smoking. During the same period, the urinary m7Gua levels significantly decreased, from 27.32 μg/mg creatinine to 14.17 μg/mg creatinine by the elimination of subjects who showed increased levels of NNAL during the smoking cessation program. The 8-OHdG levels were also reduced within the same period, but were not significantly different. From the all data analysis, the urinary levels of cotinine and NNAL positively correlated with the level of m7Gua. Conclusions NNAL may be an appropriate exposure marker for evaluating the smoking status of patients in a smoking cessation program. The urinary cotinine and NNAL levels positively correlated with the m7Gua levels.

show abstract

“…While the determinants of tobacco use are complex and include environmental and social factors (Tobacco Advisory Group of the Royal College of Physicians, 2007), the rapid absorption of a sufficient dose of nicotine has been proposed to be an important factor for consumer acceptability of tobacco and nicotine products (Foulds et al, 2003). Nicotine replacement therapy (NRT) products, on average, provide the user much slower absorption and lower maximum plasma concentration (C max ) of nicotine compared with cigarettes (Benowitz, Porchet, Sheiner, & Jacob, 1988; Russell, Jarvis, Feyerabend, & Ferno, 1983; Sobue, Sekiguchi, Kikkawa, Akasaki, & Irie, 2006). Some authorities suggest this differing pharmacokinetic profile is a contributing factor to NRT products’ limited success as aids for quitting smoking (Britton, 2008).…”

Section: Introductionmentioning

confidence: 99%

Determination of Nicotine Absorption from Multiple Tobacco Products and Nicotine Gum

Digard

Proctor

Kulasekaran

et al. 2012

Nicotine & Tobacco Research

102

View full text Add to dashboard Cite

Introduction:Snus is a smokeless tobacco product traditionally used in Scandinavia and available in pouched or loose forms. The objective of this study was to determine nicotine absorption for current pouched and loose snus products in comparison with a cigarette and an over-the-counter nicotine gum.Methods:We conducted an open-label, randomized, 6-way, crossover study involving 20 healthy snus and cigarette users. One of 6 products (2 pouched snus, 2 weights of loose snus, a cigarette, and a nicotine gum) was administered at each of 6 visits. Blood samples were taken at intervals over 120 min and sensory perception assessed by questionnaire.Results:For the 4 smokeless tobacco products and the nicotine gum, blood plasma levels of nicotine were ranked according to total nicotine content as follows: loose snus (27.1 mg nicotine) > pouched snus (14.7 mg nicotine) > loose snus (10.8 mg nicotine) = pouched snus (10.7 mg nicotine) > nicotine gum (4.2 mg nicotine). The area under the plasma concentration–time curve (AUC) and maximum plasma concentration (Cmax) of nicotine ranged from 26.9 to 13.1 ng.h/ml and 17.9 to 9.1 ng.h/ml, respectively across all the products. Nicotine was absorbed more rapidly from the cigarette but systemic exposure was within the range of the smokeless tobacco products (AUC = 14.8 ng.h/ml; Cmax = 12.8 ng.h/ml).Conclusions:This study has generated new information on comparative nicotine absorption from a cigarette, loose snus, and pouched snus typical of products sold in Scandinavia. The similar nicotine absorption for 1 g portions of loose and pouched snus with approximately 11 mg of nicotine indicate that absorption kinetics were dependent on quantity of tobacco by weight and total nicotine content rather than product form.

show abstract

Comparison of Nicotine Pharmacokinetics in Healthy Japanese Male Smokers Following Application of the Transdermal Nicotine Patch and Cigarette Smoking

Cited by 14 publications

References 32 publications

The future of vaccines in the management of addictive disorders

The future of vaccines in the management of addictive disorders

Effects of smoking cessation on biological monitoring markers in urine

Determination of Nicotine Absorption from Multiple Tobacco Products and Nicotine Gum

Contact Info

Product

Resources

About